|
|||||||||||||||||||||||
 |
Chelation Study 1 |
|
|
|||||||||||||||||||||||||||
|
What is EDTA Chelation Therapy?
Its Value & Effects Chelation Therapy is a safe, effective and relatively inexpensive treatment to restore blood flow in victims of atherosclerosis without surgery.
Chelation Therapy involves the intravenous infusion of a prescription
medicine called Ethylene Diamine Tetra-Acetic Acid (EDTA), plus vitamins
and minerals at therapeutic dosages.
EDTA helps prevent the production of harmful 'Free Radicals' through elimination. Arterial disease is responsible for strokes, heart attacks, poor circulation and memory loss. Detoxamin - EDTA chelationAn EDTA chelation therapy medical
breakthrough… For years EDTA chelation therapy has been instrumental in literally saving the lives of people across the globe. The results of this therapy have given patients a new lease on life. EDTA chelation therapy works by removing the toxic heavy metals from damaged hearts and heart valves as well as from hidden stores within blood vessels, kidneys, and more. You see, by removing the circulatory heavy metal toxins, EDTA enhances cardiovascular blood flow and function. As highly recommended as this therapy has been
in the past, the only effective way to receive the therapy has been
intravenously. This requires sitting in a doctor's office while the EDTA
is slowly introduced into your bloodstream, via IV, over a 3-4 hour
period. The time, the expense, the invasiveness of the needle and the
overall inconvenience has made this therapy out of reach to most people,
until now. We are so confident that you will experience better health once you start using Detoxamin; I understand how important this information is to you as I see patients every day with both chronic and acute health problems. From heart disease, diabetes, high blood pressure, cardiovascular diseases, chronic fatigue, cancer to prostate issues and so many more diseases prominent today, it is apparent that each have one thing in common. They are all linked to our increasing exposure to heavy metals in our environment. In my clinic, Tustin Longevity Center (TLC), I have found heavy metals in the vast majority of my patients; this is without the patients even knowing that they are carriers of heavy metals in their bodies. This is why for years I have been administering IV EDTA chelation and am fully aware of the problems associated with it. For years I have been looking for a method of EDTA chelation that offered more affordability, more convenience and safety, without losing any effectiveness. I tried Oral EDTA and other methods, and none would compare with the results I experienced with IV EDTA chelation - until I started to use Detoxamin. Clinically, my patient-population experiences demonstrate improved energy, mood and mental function as these oxidizing metals are reduced with Detoxamin. Detoxamin is the 21st century antioxidant key (along with a healthy lifestyle) needed to survive living in our toxic world. As a medical authority on Detoxamin, I truly believe Detoxamin is one of the most significant means to improve patients' overall health that I've experienced in my 30 years of practice. And as of now, I have treated more than 600 patients with Detoxamin. Why are you looking into chelation therapy? We find that the three most common reasons are:
Whatever your reason is for visiting us today, we hope we give you
what you are looking for. The benefits of using Detoxamin are astounding:
Medically equivalent to IV EDTA chelation. This is another huge aspect of why Detoxamin is so popular throughout the world. People for years have been frustrated with the inconvenient delivery of EDTA into the body. Now that this method is available, most people prefer it and in most cases the results are even better than with the IV method. For every three Detoxamin, you receive about the same dosage you would get in one IV treatment, but with a much safer and more convenient delivery method.
Mercury Toxicity and Systemic Elimination Agents Bibliography 1 Toxicological Profile For Mercury. U.S. Department Of Health & Human Services, Agency for Toxic Substances and Disease Registry, March 1999 Published by Division of Toxicology/Toxicology Information Branch, 1600 Clifton Road NE, E-29, Atlanta, Georgia 3033 2 Richardson GM. Assessment of mercury exposure and risks from dental amalgam. Medical Devices Bureau, Environmental Health Directorate, 1995 Health Canada. 3 Stajich GV, Lopez GP, Harry SW, et al. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr. 2000 May;136(5):679-81. 4 Pless R, Risher JF. Mercury, infant neurodevelopment, and vaccination. J Pediatr. Mercury, infant neurodevelopment, and vaccination. 2000 May;136(5):571-3. 5 Offit PA. Preventing harm from thimerosal in vaccines. JAMA. 2000 Apr 26;283(16):2104. 6 No authors listed. From the Centers for Disease Control and Prevention. Recommendations regarding the use of vaccines that contain thimerosal as a preservative. JAMA. 1999 Dec 8;282(22):2114-5. 7 Inouye M, Murakami U. Placental transfer of methylmercury and mercuric mercury in mice. Environ Med 1990;34:160-172. 8 Kuntz WD, Pitkin RM, Bonstrom AW, et al. Maternal and cord blood background levels. A longitudinal surveillance. Am J Obstet Gynecol 1982;143:440-443.
9. Harrison IA; Some electromchemical features of the in vivo corrosion
of dental amalgams. J Appl Electrochem 1989;19: 301-310 11 WHO. Inorganic Mercury. Geneva, Switzerland: World Health Organization, International Programme on Chemical Safety. 1991 Vol 118. 12. Skare I, Engqvist A., Human exposure to mercury and silver released from dental amalgam restorations. Arch Environ Hlth 1994;49:384-394 13. World Health Organization. Environmental Health Criteria. 118, Inorganic Mercury (Friber I, ed) WHO Geneva 1991. 14. Berry TC, Nicholson J, Torendle K.; Almost two centuries with amalgam. Where are we today? J Am Dent Assn 1994;120:394-395 15. Lorschider, F, Vimy MJ, Summers, AO: Mercury exposure from "silver" tooth fillings: Emerging evidence questions a traditional dental paradigm. FASEB J 1995; 9:504-508 16. Lorscheider F, Vimy MJ: Evaluation of the safety issue of mercury release from dental fillings. FASEB J 1993;7:1432-1433 17 Bjorkman L, Sandborgh-Englund G, Ekstrand J. Mercury in salvia and feces after removal of amalgam fillings. Toxicol Apply Pharmacol 1997;144:156-162. 18. Svare CW, Peterson LC, Reinhardt JW, Boyer DB, et.al; The effects of dental amalgams on mercury levels in expired air. J Dent Res 1981;60:1668-1671 19. Vimy MJ, Lorscheider F; Intra-oral air mercury released from dental amalgam. J Dent Res 1985;64:10069-1071 20. Aronsson AM; Lind B, Nylander M, Nordberg M; Dental amalgam and mercury. Biol Metals 1989; 2:25-30 21. Hanson M, Pleva J: The dental amalgam issue. A review. J Experentia. 1991;47:479-22 22 Zalups RK. Molecular interactions with mercury in the kidney. Pharmacol Rev 2000 Mar;52(1):113-43. 23. Hahn LJ, Kloiber R, Leininzer RW, Vimy MJ, Lorscheider FI; Whole-body imaging of the distribution of mercury released from dental fillings into monkey tissues. FASEB J 1990;4:3256-3260 24 Zahnaerztl, Knappwost et al. Abgabe von Quecksilberdampf aus Dentalamalgamen unter Mundbedingungen. Welt/Reform 1985;94, 131-138 25. Nierenberg DW, Nordgren RE, Chang MB, et al. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med. 1998;338(23): 1672-1676 26. Clarkson TW; Mercury - an element of mystery. N Engl J Med. 1990;323:1137-1139 27. The toxicological profile of mercury. 1994 publication by the US Department of Health and Human Services (Agency for Toxic Substances and Disease Registry, Division of Toxicology; 1600 Clifton Road NE E-29, Atlanta, GA 30333). 28. Eggleston DW, Nylander M.; Correlation of dental amalgam with mercury in the brain. J Prost Dent 1987;58:704-707 29. Retrograde Axonal Transport of Mercury; Bjoern Arvidson Experimental Neurology 1987;98, 198-203 30 Inorganic Mercury is Transported from Muscular Nerve Terminals to Spinal and Brainstem Motorneurons: Bjoern Arvidson Muscle and Nerve 1992;15:1089-1094 31 Handbuch der Amalgamvergifung, Max Daunderer, Ecomed Verlag, Muenchen(1996) 32 Clarkson TW, Hursh IB, Sager PR, Sverson TLM: Mercury. In Biological Monitoring of Toxic Metals (Clarkson TW, Friberg L, Nordberg CF,, and Sager PR, eds) pp 199-246. Plenum, New York 1988. 33 Klassen CD. Heavy metals and heavy-metal antagonists. In: The Pharmacological Basis of Theraputics, 8th edition(Gilman AC, Rall TW, Niew AS, Taylor P, eds) pp. 1598-1602. Pergamon Press, New York 1990. 34 Pendergrass JC, Haley BE, Vimy MJ, et al. Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer diseased brain. Neurotoxicology. 1997;18(2):315-24. 35 Pendergrass JC, Haley BE. Inhibition of brain tubulin-guanosine 5'-triphosphate interactions by mercury: similarity to observations in Alzheimer's diseased brain. Met Ions Biol Syst. 1997;34:461-78. 36 Hirsch F, Kuhn J, Ventura M, Vial MC, Fournie G, Druet P; Production of monoclonal antibodies. J Immunol 1986;136:3272-3276 37 Hultman P, Johansson U, Turley Sj, Lindh U, Enestrom S, Pollard KM; Adverse immunological effects and autoimmunity induced by dental amalgam and alloy in mice. FASEB J 1994;8:1183-1190 38 Biagazzi M, Pierlguigi E; Autoimmunity and heavy metals. Lupus 1994;3:449-453. 39 Nylander M, Frierg I, Lind B; Mercury concentrations in the human brain and kidneys in relation to exposure from dental amalgam fillings. Swed Dent J 1987;11:179-187 40 Dondero F, Lenzi A, Lombardo F, Gandini L; Therapy of immunologic infertiilty. Acta Eur Fertil 1991;22:139-145 41 Rowlands AS, Baird DD, Weinberg CP, Shore DL, Shy CM, Wilcos AJ. The effect of occupational exposure to mercury vapor on the fertility of female dental assistants. Occup Environ Med 1994;51:28-34. 42 Gerhard I, Monga B, Waldbrenner A, Runnebaum B Heavy metals and fertility. J Toxicol Environ Health 1998;21;54(8):593-611 43 Gerhard I, Frick A, Monga B: Diagnosis of mercury body burden. Clin Lab 1997;43:637-647 44 Duhr E, Pendergrasss C, Kasarskis E, Slevin J Haley B; Mercury induces GTP-tubulin interactions in rat brain similar to those observed in Alzheimer's disease. FASEB J 1991; 5:456. 45 Hultman P, Johansson U, Turle S,J, et al: Adverse immunological effects and autoimmunity induced by dental amalgam and alloy in mice. FASEB J 1994;8:1183-1190 46 Siblered TL, Kienholz E. Evidence that mercury from silver dental fillings may be an etiological factor in reduced nerve conduction velocity in multiple sclerosis patients. Journal of Orthomolecular Medicine 1997;12(3):169-172. 47 Barregard L, Lindtedt G, Shutz A, et al. Endocrine function in mercury exposed chloralkali owkers. Occup Environ Med 1994, 51 (8)536-540. 48 Moszczynski P, Lisiewica J, Bartus R, et al. Lymphocytes T and NK cells in men occupationally exposed to mercury vapors. Int J Occup Med Environ Health 1995 8(1):49-56. 49 Summers AO, Wireman J, Vimy MI, Lorscheider FI, Marshall B, Levy SB, et al; Mercury released from dental Asilver@ fillings provokes an increase in mercury and antibiotic-resistant bacteria in oral and intestinal floras of primates. Antimicrob Agents and Chemother 1993;37:825-834 50 Escheverria D, Hever N, Martin MD, Naleway CA, Woods JS Bittner AC; Behavioral effects of low level exposure to mercury among dentists. Neurotxicol Teratol 1995;17:161-168 51 Ngim CH: Chronic neurobiological effects of elemental mercury in dentists. Br J Indust Med 1992;49:782-790 52 Siblerud RL; The relationship between mercury from dental amalgam and mental health. Am J Psychotherapy 1989;18:575-587 53 Powell JE, Edwards A, Edwards M, et al. Changes in the incidence of childhood autism and other autistic spectrum disorders in preschool children from two areas of the West Midlands, UK. Dev Med Child Neurol. 2000 Sep;42(9):624-8. 54 Tanguay PE. Pervasive developmental disorders: a 10-year review. J Am Acad Child Adolesc Psychiatry. 2000 Sep;39(9):1079-95. 55 Rice D, Barone S Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect. 2000 Jun;108 Suppl 3:511-33. 56 Frustaci A, Magnavita N, Chimenti C, et. al; Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy. J Am Coll Cardiology 1999;33:1578-83 57 Chang YC, Yeh C, Wang JD. Subclinical neurotoxicity of merucyr vapor revcelaed by a multimodality evoked potential study of chloralkali workers. Amer J Ind Med 1995;27(2):271-279. 58 Yang Y-J, Huang C-C, Shih T-S, et al . Chronic elemental mercury intoxication:clinical and field studies in lampsocked manufacturers. 1994;Occup Environ Med 57(1):245-247. 59 Bluhm RE, Bobbitt RG, Wlech LW, et al. Elemental mercury vapour toxicity, treatment and prognosis after acute intensive exposure in chloraklali plant workers. Part 1I. History, neuropsychological findings and chelator effects. Hum Exp Toxicol 1992 11(3):201-210. 60 Clarkson TW. Mercury. 1989; J Am Coll Toxicol 8(7):1291-1296. 61 Eley BM The future of dental amalgam: A review of the literature. Part 2: Mercury exposure in dental practice. Br Dent J 1997;182(8):293-7. 62 Petrunkin VE: Synthesis and properties of demercapto derivatives of alkylsulfonic acids. Toksikol mosc 1958;21: 53-59 63 Torres-Alanis O, Garza-Ocanas L, Pineyro-Lopez A. Evaluation of urinary mercury excretion after administration of 2,3-dimercapto-1-propane sulfonic acid to occupationally exposed men. J Toxicol Clin Toxicol 1995;33(6):717-720 64 Aaseth J, Jacobsen D, Andersen O, Wickstrom E. Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate. 1995;120(3):853-854 65 Aposhian HV, Maiorino RM, Rivera M, et al Human studies with the chelating agents, DMPS and DMSA. J Toxicol Clin Toxicol 1992;30(4):505-528 66 Aposhian HV, Aposhia MM. Meso-2,3 dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Toxicol 1990;30:279-306 67 Lorscheider FL, Vimy MJ. Evaluation of the saftey issue of mercury release from dental fillings. FASEB J 1993;7:432-1433 68 Aposhian VK: Mobilization of Mercury and Arsenic in Humans by Sodium 2,3 Dimercapto-1-propane Sulfonate (DMPS). Environ Health Perspect 1998;106(Suppl 4):1017-1025 69 Crinnion WJ. Environmental medicine, part three: long-term effects of chronic low-dose mercury exposure Altern Med Rev 2000 Jun;5(3):209-23 70 Schiele R, Schaller KH, Welte D: Mobilization of mercury reserves in the organism by means of DMPS. Occup Med Soc Med Prevent Med 1989;24: 249-251 71 Kidd RF Results of dental amalgam removal and mercury detoxification using DMPS and neural therapy. Altern Ther Health Med 2000 Jul;6(4):49-55 72 Belles M, Sanchez DJ, Gomez M, Domingo JL, Jones MM, Singh PK Assessment of the protective activity of monisoamyl meso-2,3-dimercaptosuccinate against methylmercury-induced maternal and embryo/fetal toxicity in mice. Toxicology 1996;106(1-3):93-97 73Kostial K, Restek-Samarzija N, Blanusa M, Piasek M, Prester L, Jones MM, Singh PK Racemic-2,3-dimercaptosuccinic acid for inorganic mercury mobilization in rats. J Appl Toxicol 1997;17(1):71-74 74 Gerhard I; Runnebaum B: Schadstoffe und Fertiliatatsstorungen Schwermetalle und Mineralstoffe. Geburtshilfe Frauenheillkd 1992;52:383-396, 509-515 75 Baum CR Treatment of mercury intoxication. Curr Opin Pediatr 1999 Jun;11(3):265-8 76 Vamnes JS, Eide R, Isrenn R, Hol PJ et al. Diagnostic value of a chelating agent in patients with symptoms allegedly caused by amalgam fillings.J Dent Res 2000 Mar;79(3):868-74 77 Sallsten G, Barregard L, Schutz A Clearance half life of mercury in urine after the cessation of long term occupational exposure: influence of a chelating agent (DMPS) on excretion of mercury in urine. Occup Environ Med 1994;51(5):337-342 78 Afonne OJ, Orisakwe OE, Ndubuka GI, et al. Zinc protection of mercury-induced hepatic toxicity in mice. Biol Pharm Bull 2000 Mar;23(3):305-8 79 Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 1995;31;97(1-3):23-38 80 Gonzalez-Ramirez D, Maiorino RM, Zuniga-Charles M, et al Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans: II. Urinary mercury, porphyrins and neurobehavioral changes of dental workers in Monterrey, Mexico. J Pharmacol Exp Ther 1995;272(1):264-274 81 Kostial K, Restek-Samarzija N, Blanusa M, Piasek M, Jones MM, Singh PK Combined oral treatment with racemic and meso-2,3-dimercaptosuccinic acid for removal of mercury in rats. Pharmacol Toxicol 1997;81(5):242-244 82 Miller AL. Dimercaptosuccinic acid (DMSA), a non-toxic, water-soluble treatment for heavy metal toxicity. Altern Med Rev. 1998;3(3): 199-207 83 Hurlbut KM, Maiorino RM, Mayersohn M, Dart RC, Bruce DC, Aposhian HV Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther 1994;268(2):662-668 84 Zheng W, Maiorino RM, Brendel K, Aposhia HV. Determination and metabolism of dithiol chelating agents. Fundam Appl Toxicol 1990;14:598-607 85 Aposhian HV. Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate. Environ Health Perspect 1998;106 Suppl 4:1017-1025 86 Research data presented at the annual meeting of the Australasian Society of Oral medicine and Toxicology in Sydney, Australia, Sept.1998 87 H.B.Xue, W.Stumm, L.Sigg: The binding of Heavy Metals to Algal Surfaces, Water Res 1988;22, 917 88 Ahner, AB, Kong KS, Morell MM, Phytochelatin production in marine algea: An interspecies comparison. Limnol Oceanograph 1995;40: 649-657 89 Carr HP, et al. Characterization of the cadmium-binding capacity of Chlorella vulgaris. Bull Environ Contam Toxicol. 1998;60(3): 433-440 90 M. Tsezos: Biosorption of Radioactive Species, in: Biosorption of Heavy Metals, pp 45-50 editied by B.Volesky, CRC Press(1990) 91 M.Kraft: Bindungsverhalten von Arsen, Cadmium, Chrom, Quecksilber, Nickel und Blei an schwerverdauliche Lebensmittel und Lebensmittelkomponenten in kuenstlichem Magen-Darm-Saft. PhD Thesis. Institut fuer Hygiene, Sozial-und umweltmedizin der Ruhr-Universitaet Bochum, Germany, (1998) 92 Klinghardt, D: Amalgam/Mercury Detox as a Treatment for Chronic Viral, Bacterial, and Fungal Illnesses Explore! Volume 1997;8, No 3 93 R.Muzzarelli, O.Tubertini: Chitin and chitosan on chromatographic supports and adsorbents for collection of metal ions from organic and aqueous solutions and sea water, Talanta, 1969;16, 1571 ff 94 Y.Subramanian, T.Yoshinar: Studies on the formation of chitin-metal complexes, Rep.No 27, Marine Sciences Center, Mc Gill Univ, Montreal (1974) 95 J.W.Park, M.O. Park: Mechanism of metal ion binding to chitosan in solution, cooperative inter- and intramolecular chelations. Bull.Korean Chem.Soc. 1984;5(3), 108 96 Omura Y, Beckman SL Role of mercury (Hg) in resistant infections & effective treatment of Chlamydia trachomatis and Herpes family viral infections (and potential treatment for cancer) by removing localized Hg deposits with Chinese parsley and delivering effective antibiotics using various drug uptake enhancement methods. Acupunct Electrother Res. 1995;20(3-4): 195-229 97 Omura Y, Shimotsuura Y, Fukuoka A, Fukuoka H, Nomoto T. Significant mercury deposits in internal organs following the removal of dental amalgam, & development of pre-cancer on the gingiva and the sides of the tongue and their represented organs as a result of inadvertent exposure to strong curing light (used to solidify synthetic dental filling material) & effective treatment: a clinical case report, along with organ representation areas for each tooth. Acupunct Electrother Res. 1996 ;21(2): 133-160. 98 Ewan KB, Pamphlett R Increased inorganic mercury in spinal motor neurons following chelating agents. Neurotoxicology 1996;17(2):343-349 99 Cha CW A study on the effect of garlic to the heavy metal poisoning of rat. J Korean Med Sci 1987;2(4):213-224 100 Lee JH, Kang HS, Roh Protective effects of garlic juice against embryotoxicity of methylmercuric chloride administered to pregnant Fischer 344 rats. J Yonsei Med J 1999 Oct;40(5):483-9 101 The Miracle of MSM The Natural Solution for Pain. Jacob, S., Lawrence, RM, Zucker, M. Penguin Putnam, New York, NY 1999. 102 Stjernberg L, Berglund J. Garlic as an insect repellent. JAMA. 2000 Aug 16;284(7):831. 103 Fleischauer AT, Poole C, Arab L. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr. 2000 Oct;72(4):1047-52. 104 Morelli V, Zoorob RJ. Alternative therapies: Part II. Congestive heart failure and hypercholesterolemia. Am Fam Physician. 2000 Sep 15;62(6):1325-30. 105 Chang, L.W , Gilbert,M and Sprecher,J: Modification of methylmercury neurotoxicity by vitamin E, Environ.Res. 1978;17:356-366 106 Yoneda S, Suzuki KT Detoxification of mercury by selenium by binding of equimolar Hg-Se complex to a specific plasma protein. Toxicol Appl Pharmacol 1997;143(2):274-280 107 Akesson I, Ingrid B; Status of mercury and selenium in dental personnel: Impact of amalgam work and own fillings. Arch Environ Health 1991;46(2):103-109 108 Johansson E: Selenium and its protection against the effects of mercury and silver. J Trace Elements 1991;5:273-274 109 Gailer J; George GN; Pickering IJ, et al. Structural Basis of the Antagonism between Inorganic Mercury and Selenium in Mammals. Chem Res Toxicol 2000 Nov 20;13(11):1135-1142 110 Hultberg B, Andersson A, Isaksson A Thiol and redox reactive agents exert different effects on glutathione metabolism in HeLa cell cultures.Clin Chim Acta 1999 May;283(1-2):21-32 111 Westphal GA; Schnuch A; Schulz TG, et al. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int Arch Occup Environ Health 2000 Aug;73(6):384-8. 112 Schurz(1) F; Sabater-Vilar M; Fink-Gremmels J. Mutagenicity of mercury chloride and mechanisms of cellular defence: the role of metal-binding proteins. Mutagenesis 2000 Nov;15(6):525-530 113 Anuradha B, Varalakshmi P Protective role of DL-alpha-lipoic acid against mercury-induced neural lipid peroxidation. Pharmacol Res 1999 Jan;39(1):67-80 114 Ballatori N, Lieberman MW, Wang W N-acetylcysteine as an antidote in methylmercury poisoning. Environ Health Perspect 1998 May;106(5):267-71 115 Dirks M, Marvin J; Mercury excretion and intravenous ascorbic acid. Arch Environ Health 1994;49(1):49-52
116 Hill, CH. Interactions of vitamin C with lead and mercury. Ann N Y
Acad Sci 1980;355:262-6 118 Zorn NE, Smith JT A relationship between vitamin B12, folic acid, ascorbic acid, and mercury uptake and methylation.Life Sci 1990;47(2):167-73 119 Sorg O, Schilter B, Honegger P, et. al. Increased vulnerability of neurones and glial cells to low concentrations of methylmercury in a prooxidant situation. Acta Neuropathol (Berl) 1998 Dec;96(6):621-7 120 Iyengar GV; Nair PP. Global outlook on nutrition and the environment: meeting the challenges of the next millennium. Sci Total Environ 2000 Apr 17;249(1-3):331-46. 121 Chen WY, Abatangelo G.Functions of hyaluronan in wound repair. Wound Repair Regen 1999;7(2):79-89 122 Delpech B, Girard N, Bertrand P, Courel MN, Chauzy C, Delpech Hyaluronan: fundamental principles and applications in cancer. J Intern Med 1997;242(1):41-8 123 Sutherland IW. Novel and established applications of microbial polysaccharides. Trends Biotechnol 1998;16(1):41-6 124 Knudson CB, Nofal GA, Pamintuan L, Aguiar DJ: The chondrocyte pericellular matrix: a model for hyaluronan-mediated cell-matrix interactions. Biochem Soc Trans 1999;27(2):142-
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||
